

































































































































































Ageing researchers and the general public have long 
been intrigued by centenarians because these subjects 
managed to avoid, postpone or overcome the major age-
related diseases such as cancer [1], cardiovascular 
diseases [2], diabetes [3], osteoporotic fractures [4] and 
dementia [5, 6].  
 
We find it useful to further distinguish centenarians from 
semi-supercentenarians (i.e. subjects that reach the age of 
105 years, 105+) and supercentenarians (subjects that 
reach the age of 110 years, 110+) because subjects in 
these latter categories are extremely rare. As of January 
1, 2015, in Italy 100+ are 19,095 out 60,795,612 living 
individuals, 105+, which constitute a subgroup of 100+, 
are 872 (1:69,720 living individuals) and 110+, which 
constitute an even smaller subgroup, are 27 (1:2,251,689 
living individuals), according to the data base from the 
Italian National Institute of Statistics [7]. On the whole, 
105+ and 110+ subjects have to be considered very rare 
cohorts of particular interest for the study of both the 
ageing phenotype and the healthy ageing determinants. 
This means that 105+ and 110+ are most informative for 
ageing research, even if it is not yet known whether 105+ 
reach the last decades of their life according to a 
molecular trajectory which progresses at a normal rate of 
change or whether the attainment of this remarkable age 
results from a slower molecular ageing rate.  
 
A rich literature describes the relationship between 
blood-based markers and age [8-12] and many genetic 
studies were devoted to clarify whether exceptional 
longevity is a highly heritable trait [13-17]. More 
recently, a variety of "omics" studies have looked at 
gene expression [18-21], metagenomic [22] or 
lipidomic [23, 24] data. Different from genetic studies, 
functional genomic studies of centenarians face the 
challenge of identifying a proper control group, as 
















longer available. To address this challenge, we decided 
to compare the centenarians’ offspring (CO) with the 
offspring of shorter-lived controls. CO are useful for 
finding suitable molecular markers and for estimating 
the trajectories of healthy ageing [25] because: i) 
longevity runs in families, which probably reflects 
shared genetic, epigenetic and environmental factors; ii) 
CO are on average 20-30 years younger than their 
centenarian parent, i.e. they are in their seventies or 
eighties, which is a critical age when the physiological 
decline and the onset of the major age-related diseases 
may occur; iii) it is feasible to recruit controls for CO 
that are age-matched and born from non-centenarian 
parents [25]. The comparison of CO to age matched 
controls has already been successfully applied to 
identify biochemical and metabolomics parameters 
related to exceptional longevity [24, 26-31] and to 
define survival scores [32, 33].  
 
Many biomarkers of different origin have been used to 
disentangle the complexity underlying the ageing 
phenotype, e.g. inflammatory biomarkers [28-31], N-
glycans [34-37] and telomere length. Telomere length is 
an attractive biomarker of ageing because a) telomere 
length shortening plays an essential role in the in vitro 
ageing of somatic cells and b) telomeres of different 
organs/cells are known to shorten with age [38-42]. 
While telomere erosion is clearly linked to ageing, a 
rich body of literature suggests that it is not the sole 
reason for in vivo ageing. For example, no significant 
association could be observed between telomere length 
and survival among the elderly and oldest old in Danish 
[43] and Japanese [28] populations.  
 
Several recent studies propose biomarkers of ageing 
based DNA methylation levels [44-49]. DNA 
methylation levels give rise to powerful epigenetic bio- 
markers of ageing since chronological age (i.e. the 
calendar years that have passed since birth) has a 
profound effect on DNA methylation levels in most 




humans. Here we test whether  families with extreme  longevity are epigenetically distinct  from controls according to an
epigenetic biomarker of ageing which is known as “epigenetic clock”. We analyze the DNA methylation levels of peripheral
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human tissues and cell types [50-59]. While previous 
epigenetic biomarkers of ageing apply to a single tissue, 
the recently developed "epigenetic clock" (based on 353 
dinucleotide markers known as Cytosine phosphate 
Guanines or CpGs) applies to most human cell types, 
tissues, and organs [48]. Predicted age, referred to as 
“DNA methylation age” (DNAm age), correlates with 
chronological age in sorted cell types (CD4 T cells, 
monocytes, B cells, glial cells, neurons), tissues and 
organs including whole blood, brain, breast, kidney, 
liver, lung, saliva [48] and even prenatal brain samples 
[60]. The epigenetic clock is an attractive biomarker of 
ageing because a) it applies to most human tissues, b) 
its accurate measurement of chronological age is 
unprecedented [61], c) it possesses independent 
predictive value for all-cause mortality [62], d) it 
correlates with measures of cognitive and physical 
fitness in the elderly [63] and e) it has been found useful 
for detecting accelerated ageing effects due to obesity 
[64], Down syndrome [65] and HIV infection [66]. 
Furthermore, it demonstrates that the cerebellum ages 
more slowly than other brain regions [67].  
 
Here, we analyze a novel peripheral blood mononuclear 
cells (PBMCs) methylation data set in an unprecedented 
Italian population of 105+, in their relative CO and in a 
cohort of healthy controls age- and sex-matched in 
respect of the CO group in order to test the hypothesis 







We used the Illumina Infinium 450K array to generate 
DNA methylation data from PBMCs of 192 Italian 
subjects. We removed 8 samples (7 semi-
supercentenarians and 1 control) from the analysis 
because they were potential outliers according to an 
unsupervised hierarchical clustering analysis based on the 
inter-array correlation. Our subsequent epigenetic clock 
analysis involved 3 distinct groups. The first group 
involved 75 subjects (mean age: 106 years, age range 
from 99 to 113 years) will be referred to as semi-
supercentenarians (105+) although it included one subject 
aged 99. The second group, CO, involved 63 offspring 
from centenarians (mean age: 72 years, age range from 
50 to 89 years). The third group involved 46 control 
subjects (mean age: 70 years, age range from 52 to 85 
years), i.e. subjects who did not have a centenarian 
parent. The first group (semi-supercentenarians), the 
second (CO) and the third group (controls) contained 59, 
25 and 37 females, respectively. By design, CO did not 
differ from controls in terms of gender (p=0.8) or 
chronological age (p=0.31). 
 
Accuracy of the epigenetic clock 
 
DNAm age (also referred to as “epigenetic age”) was 
calculated using the DNA methylation levels of PBMCs 
applying a previously described method [48].  
 
DNAm age was highly correlated with chronological 
age across all samples (correlation r=0.89, Figure 1A).  
 
Three measures of epigenetic age acceleration 
 
In this article, we consider three measures of epigenetic 
age acceleration (as detailed in Methods). The first one, 
which will be referred to as universal measure of age 
acceleration (denoted Age Accel), applies to virtually 
all tissues and cell types (with the exception of sperm) 
[48]. The other two measures (referred to as intrinsic 
and extrinsic age acceleration, respectively) only apply 
to blood. The universal measure is defined as the 
difference between DNAm age value and the value 
predicted by the linear regression model in groups 1 and 
2 (i.e. in semi-supercentenarians or their offspring). The 
term "universal" refers to the fact that this measure can 
be defined in a vast majority of tissues and cell types 
[48]. A positive value of the universal age acceleration 
measure indicates that DNA methylation age is higher 
than that predicted from the regression model for COs 
or semi-supercentenarians of the same age. 
 
The measure of intrinsic epigenetic age acceleration 
(IEAA) measures "pure" epigenetic ageing effects in 
blood that are not confounded by differences in blood 
cell counts.  
 
The measure of extrinsic epigenetic age acceleration 
(EEAA) aims to measure ageing in immune related 
components also relates to age-related changes in blood 
cell composition such as the decrease of naive CD8+ T 
cells and the increase in memory or exhausted CD8+ T 
cells [29, 68-70]. EEAA is defined on the basis of a 
weighted average of the epigenetic age measure from 
Hannum et al (2013) [47] and three blood cell types that 
are known to change with age: naive (CD45RA+CCR7+) 
cytotoxic T cells, exhausted (CD28-CD45RA-) cytotoxic 
T cells and plasma B cells. By definition, EEAA has a 
positive correlation with the amount of exhausted CD8 T 
cells and plasma blast cells and a negative correlation 
with the amount of naive CD8+ T cells. Blood cell counts 
were estimated based on DNA methylation data as 
described in Methods (section "Estimating blood cell 
counts based on DNA methylation levels").  
 
  























































































































Covariate Coefficient Std. Error T statistic P-value 
Offspring -3.804 1.043 -3.647 0.00043 
Age 0.743 0.071 10.442 < 2x10-16 
Sex (female) 0.174 1.065 0.163 0.87 
Naïve CD8+T cell -0.007 0.011 -0.617 0.54 
Exhausted CD8+ T cell -0.044 0.159 -0.274 0.79 
Plasma Blast cell -7.62 3.706 -2.055 0.042 
Helper T cell (CD4) -28.3 8.728 -3.247 0.0016 
Natural Killer cell 12.5 7.962 1.572 0.13 
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The three different measures of epigenetic age 
acceleration are not independent of each other. The 
universal measure Age Accel has a moderately high 
correlation with IEAA (r=0.65, p=1.8x10-23) and with 
EEAA (r=0.71, p=1.6x10-29). But IEAA has only a 
weak correlation with EEAA (r=0.19, p=0.01). By 
construction, our three measures of epigenetic age 
acceleration are uncorrelated (r=0) with chronological 
age at the time of blood draw. 
 
Offspring of semi-supercentenarians have a slow 
intrinsic ageing rate  
 
We find that PBMCs of the offspring of 105+ age more 
slowly than that of age matched controls according to a) 
the Age Accel measure (Kruskal Wallis test p=0.012, 
Figure 1C) and b) the intrinsic measure of age 
acceleration (p=0.0016 Figure 1E). According to a 




































1), CO are 5.1 years younger (p=0.00051) than age 
matched controls even after adjusting for sex and 
estimated blood cell counts. 
 
Semi-supercentenarians appear to age more slowly 
than expected 
 
Interestingly, the DNAm age of 105+ is systematically 
lower than their chronological age as can be seen from 
the fact that the red dots lie beneath the black line in 
Figure 1A. The DNAm age of 105+ differs significantly 
from that of controls (p=0.028) but not from that of the 
CO (p=0.29) according to a multivariate model analysis 
(Table 2) that adjusted for chronological age, sex, and 
estimated blood cell counts. According to this model, 
105+ are on average 8.6 years younger than expected 
based on chronological age. The systematic 
underestimate of age in centenarians has also been 


































































































































































StatusControlvsCentenarian 6.583 2.98 2.208 0.029 
StatusOffspringvsCentenarian 3.03 2.84 1.069 0.29 
Age 0.765 0.080 9.578 < 2x10-16 
Sex (female) -1.025 1.02 -1.005 0.32 
Naïve CD8+T cell -0.014 0.010 -1.444 0.15 
Exhausted CD8+ T cell -0.118 0.142 -0.832 0.41 
Plasma Blast cell -6.046 2.83 -2.135 0.034 
Helper T cell (CD4) -38.069 7.53 -5.054 1.1x10-6 
Natural Killer cell -1.926 7.25 -0.265 0.79 
Monocyte -14.782 8.00 -1.848 0.066 
Coefficients and p‐values from regressing DNAm age on offspring status, age, sex, and various blood 
cell counts  in non‐centenarian subjects (subjects younger than 90). The model explained 85% of the 







(A)  reports  a  percentage while  that  for  (B,  C)  corresponds  to  counts  but  it  is  best  to  interpret  the  y‐axis  in  (A‐C)  as  ordinal
abundance measure. The y‐axis in (D‐H) reports estimated proportions based on the Houseman method [78]. 
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While our results in the CO suggests that the age 
difference of 8.6 years reflects a lower epigenetic 
ageing rate in 105+, we cannot rule out that 
confounders play a role as well (due to the lack of 
suitable controls for centenarians). 
 
Extrinsic age acceleration and blood cell counts are 
not significant  
 
The CO do not differ from age matched controls in 
terms of the extrinsic measure of age acceleration 
(Figure 1F) or in terms of estimated blood cell counts 
(Figure 2) but future studies with large samples should 
revisit these analyses. When comparing 105+ to 
younger subjects (CO and controls), we find that 105+ 
contain more exhausted cytotoxic T cells (Figure 3A), 
fewer naïve cytotoxic T cells (Figure 3B), fewer naïve 
helper T cells (Figure 3C), more cytotoxic T cells 
(Figure 3D), fewer helper T cells (Figure 3E), more 
natural killer cells (Figure 3F), and fewer B cells 
(Figure 3G). These findings are congruent with those 
from many previous studies of age related changes in 




This article leverages three epigenetic biomarkers of 
ageing to characterize semi-supercentenarians and their 
offspring. 
 
To the best of our knowledge, this is the first study that 
demonstrates that the offspring of semi-supercentenarians 
have a lower intrinsic epigenetic ageing rate in PBMCs. 
A similar trend was reported by Gentilini [73] that, by 
analyzing whole-genome methylation data from PBMCs 
in a smaller cohort (including 21 female centenarians, 
their 21 female offspring, 21 offspring of both non-long-
lived parents and 21 young women), observed an age-
related decrease in global DNA methylation and a delay 
of this process in centenarians' offspring. In the present 
study, the reported p-values (p=0.00051 in Table 1, 
p=0.012 in Figure 1C) remain significant even after 
adjusting for multiple comparisons since our study only 
involved three major hypothesis tests corresponding to 
the three related measures of epigenetic age acceleration 
(i.e. Age Accel, IEAA, EEAA). This remarkable finding 
is mirrored by the result that semi-supercentenarians 
appear to be younger (8.6 years, Table 2) than expected 
based on chronological age. Future studies will be needed 
to investigate how an epigenetic trajectory of healthy 
ageing relates to that of clinical measures of 
physiological or pathological ageing. 
 
Strengths of this study include a) access to PBMCs 
from a unique collection of semi-supercentenarians and 
their offspring; b) careful matching between the 
offspring of semi-supercentenarians and unrelated 
control offspring from non-centenarians; c) state of the 
art epigenetic biomarkers of ageing. The following 
limitations need also to be acknowledged. First, our 
results should be replicated in other populations (ideally 
involving semi-supercentenarians and their offspring) 
who differ from our Italian cohort in terms of genetic 
background, lifestyle and cultural habits. Further, it will 
be of great interest to extend this kind of epigenetic 
clock analysis to other accessible fluids and tissues such 
as buccal epithelium, saliva, skin, adipose, muscle. It is 
beyond the scope of this article to carry out an 
epigenome wide association studies (EWAS) based on 
486k individual CpGs on the Illumina array. The 
number of semi-supercentenarians included in this study 
is relatively small but these subjects are very rare, i.e. 
about one in 69,720 Italian living individuals and 6 out 
of the top 50 oldest living people are Italian 
(https://en.wikipedia.org/wiki/List_of_oldest_living_people). 
 
The epigenetic clock and related methylation-based 
biomarkers of ageing are arguably the most accurate 
measures of the wider process of epigenetic remodeling 
that occurs in different cell types, tissues and organs 
during human ageing [46, 48, 74, 75]. Previous studies 
have shown that epigenetic age relates to cognitive 
status, physical fitness, and all-cause of mortality in 
aged populations [62, 63, 79-81]. The current study 
adds to an increasing body of evidence that suggests 
that the epigenetic age of PBMCs relates to biological 
age or physiological age but other complementary 
biomarkers of ageing undoubtedly play a crucial role. It 
is highly unlikely that a single blood-based biomarker 
of ageing (such as epigenetic age) captures all aspects 
of physiological age.  
 
Overall, our results suggest that the offspring of semi-
supercentenarians are informative when it comes to 
detecting epigenetic determinants of healthy ageing. By 
understanding why the offspring of centenarians are 
protected against epigenetic ageing, we might be able to 
learn how to extend the benefits of successful ageing to 
the general population. 
 
MATERIALS AND METHODS 
 
Description of the dataset. The subjects were recruited 
in three Italian centers (Bologna , Milan and University 
of Calabria at Rende). The study was approved by the 
local Ethical Committee (S. Orsola Hospital - 
University of Bologna; Prot. n. 2006061707, 
amendment 08/11/2011; Fondazione IRCCS Cà Granda 
Ospedale Maggiore Policlinico, Prot. n. 2035, 
amendment 30/11/2011; University of Calabria 
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9/9/2004 amendment on 24/11/2011). A written 
informed consent form was obtained from all 
participants. 
 
This novel dataset (measured on the Illumina 450K 
array) includes 192 subjects: 82 semi-supercentenarians 
(33 from Bologna, 29 from Milan and 20 from 
Calabria), 63 offspring of semi-supercentenarians (22 
from Bologna, 28 from Milan and 13 from Calabria) 
and 47 control subjects whose parents were not 
centenarians (16 from Bologna, 17 from Milan and 14 
from Calabria). 
 
DNA extraction and bisulphite treatment of DNA. 
Extraction of genomic DNA from PBMCs was 
performed using the AllPrep DNA/RNA/protein kit 
(QIAGEN, Hilden, Germany). Sodium bisulphite 
conversion for Infinium HumanMethylation450 
BeadChip was performed using the EZ-DNA 
Methylation-Gold Kit and the EZ-96 DNA Methylation 
Kit respectively Genome-wide DNA methylation was 
analyzed using the Infinium HumanMethylation450 
BeadChip (Illumina, San Diego, CA) following 
manufacturer’s instructions. Arrays were scanned by 
HiScan (Illumina). GenomeStudio (Illumina) was used 
to perform background subtraction. 
 
DNA methylation age and epigenetic clock. The 
epigenetic clock software implements a data 
normalization step that repurposes the BMIQ 
normalization method from Teschendorff [76] so that it 
automatically references each sample to a gold standard 
based on type II probes as detailed in Additional file 2 
from [48]. All of the described epigenetic measures of 
ageing and age acceleration are implemented in our 
freely available software [48]. The epigenetic clock is 
defined as a prediction method of age based on the 
DNA methylation levels of 353 CpGs. Predicted age, 
referred to as DNAm age, correlates with chronological 
age in sorted cell types (CD4 T cells, monocytes, B 
cells, glial cells, neurons), tissues and organs, including: 
whole blood, brain, breast, kidney, liver, lung, saliva 
[48]. Mathematical details and software tutorials for the 
epigenetic clock can be found in the Additional files of 
[48]. An online age calculator can be found at our 
webpage (https://dnamage.genetics.ucla.edu).  
 
Measures of epigenetic age acceleration. The name of 
our universal measure of age acceleration (Age Accel) 
reflects that it applies to virtually all sources of human 
DNA (with the exception of sperm). Here we defined it 
as follows. First, we regressed DNAm age on 
chronological age in semi-supercentenarians and their 
offspring. Next, we used the resulting model to predict 
the age subject. Next the universal measure was defined 
as the difference between the observed measure of 
DNAm age and the predicted value. Thus, a high 
positive value for Age Accel indicates that the observed 
DNAm age is higher than that predicted based on semi-
supercentenarians and their offspring. Age Accel has a 
relatively weak correlation with blood cell counts [66] 
but it still relates to estimated blood cell counts as can 
be seen from Table 1. To subtract out the effect of blood 
cell counts, we find it useful to define a measure of 
intrinsic epigenetic age acceleration (IEAA) that 
measures "pure" epigenetic ageing effects that are not 
confounded by differences in blood cell counts. It is 
defined as the residual resulting from a multivariate 
regression model of DNAm age on chronological age 
and various blood immune cell counts (naive CD8 T 
cells, exhausted CD8 T cells, plasma B cells, CD4 T 
cells, natural killer cells and monocytes).  
 
The measure of extrinsic epigenetic age acceleration 
(EEAA) aims to measure epigenetic ageing in immune 
related components. EEAA is defined using the 
following three steps. First, we calculated the epigenetic 
age measure from Hannum et al (2013) [47], which is 
weakly correlated with certain blood cell types [62]. 
Second, we increased the contribution of blood cell 
types to the age estimate by forming a weighted average 
of the Hannum’s estimate with 3 cell types that are 
known to change with age: naive (CD45RA+CCR7+) 
cytotoxic T cells, exhausted (CD28-CD45RA-) 
cytotoxic T cells, and plasma B cells using the approach 
of [77]. The resulting measure of blood age is referred 
to as BioAge4 in our epigenetic clock software. Third, 
we defined a measure of age acceleration (EEAA) as the 
residual resulting from a univariate model regressing 
BioAge4 on chronological age. By definition, our 
measure of EEAA has a positive correlation with the 
amount of exhausted CD8 T cells and plasma blast cells 
and a negative correlation with the amount of naive 
CD8+ T cells. Blood cell counts were estimated based 
on DNA methylation data as described in the section 
entitled "Estimating blood cell counts based on DNA 
methylation levels". By construction, EEAA tracks both 
age related changes in blood cell composition and 
intrinsic epigenetic changes.  By definition, none of our 
three measures of epigenetic age acceleration are 
correlated with the chronological age. 
 
Estimating blood cell counts based on DNA 
methylation levels. We estimate blood cell proportions 
using two different software tools. Houseman's 
estimation method [78], which is based on DNA 
methylation signatures from purified leukocyte samples, 
was used to estimate the proportions of cytotoxic 
(CD8+) T cells, helper (CD4+) T, natural killer B cells. 
The advanced analysis option of the epigenetic clock 
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software [48] was used to estimate the percentage of 
exhausted CD8+ T cells (defined as CD28-CD45RA-) 
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